Episodes

In this podcast, we talked with Dr. Glenn Harris, Director of Integrated Life Sciences Platforms at 908 Devices, about the benefits and challenges of implementing rapid media analysis in process development, including the bottleneck created by outsourcing samples to core labs. We also discussed an easy to implement, benchtop media analyzer that permits comprehensive media analysis in real-time, thus speeding process development efforts. I started the interview by asking Glenn if he could explai...

In this podcast, we talked with Dr. Tobias Hertzig, Regulatory Affairs Manager and Dr. Ulrich Tillmann, Global Product Manager, Supplements and Manufacturing Aids both representing Merck KGaA, Darmstadt, Germany. We discussed non-animal origin cell culture media supplements, including regulatory advantages, performance metrics and their use in biologics manufacturing. I began our discussion by asking Tobias if he could give us a definition of what non-animal origin means and if there was an ind...

Dr. Jennifer Chain, Scientific Director of Research and Development, Oklahoma Blood Institute, talks about the isolation of mesenchymal stem cells form cadaveric bone marrow and the differences between live and cadaveric donors

Max Blomberg and Andrew Govea talk about the challenges of handling bulk drug substance, specifically freeze and thaw and how the need for scalability, flexibility, and a robust approach led to the development of CryoVault.

Paul Jantzen, Product Manager for IncuCyte at Sartorius talks about the benefits of real-time live-cell analysis and image processing workflows. We also discussed how live-cell analysis is enabling the use of neuronal cell models to study cell health, morphology, function and cell dynamics.

Jonathan Royce details new technologies to monitor critical quality attributes, reduce development time and increase the number of projects that can be run.

Dr. Paul Wotton, Chief Executive Officer, Obsidian Therapeutics talks about the evolution of cancer therapy and new advancements in the space including precision medicine. Our discussion included Obsidian's cytoDRiVE™ platform that provides a technology, in which the level and timing of protein activity are fully controlled in a dose-dependent manner by an FDA-approved small molecule.

In this podcast, Susana Alcantara, Senior R&D Scientist and Neuroscience Program Leader, BioAnalytics, Sartorius talks about the ways real-time live cell analysis is enabling neuroscience research. We also discussed how real-time cell analysis can be used in neurological disease model development and in studying disease pathology to enable drug discovery.

Shareen Doak and Dr. Wolfgang Moritz talk about the use of 3D cell-based human liver microtissue models to predict the adverse effects of chronic exposure to nanomaterial . We also discussed the use of liver microtissue models for drug discovery and development.

W interviewed Cory Card, Principal Scientist Life Sciences, GE Healthcare about raw material quality, its impact on cell culture and technologies to identify and mitigate raw material variation.

In this podcast, we interviewed Dr. J.J. Luo, Executive Director and Dr. Lily Yin, Head of Biologics Conjugation Development, at WuXi Biologics about the state of the ADC marketplace and the challenges in developing antibody drug conjugates. We then dove into reasons behind why they built a dedicated manufacturing facility for ADCs and other bioconjugates and how a single-source development platform can benefit bioconjugate drug development efforts. Podcast Notes: I began the podcast by asking...

In this podcast, we interviewed Dr. Manny Litchman, President and CEO, Mustang Bio and Dr. Knut Niss, Chief Technology Officer, Mustang Bio about the exciting study results for their gene therapy candidate to treat X-SCID, why this disease is a good fit for gene therapy and next steps. Show Notes To begin the podcast, I asked Dr. Litchman about the study results in treating X-SCID or “bubble boy disease”, including current standard of care and why gene therapy is a good fit for this disease. H...

In this podcast, we interviewed Dr. Andreas Castan, Principal Scientist at GE Healthcare Life Sciences about the best methods for optimizing perfusion processes. This included a discussion of tools for media optimization and innovative cell separation techniques. Show Notes I began the podcast by asking Dr. Castan what makes perfusion a good manufacturing platform? He identified several reasons including short residence times in the bioreactor through adding fresh media and removal of spent me...

In this podcast and accompanying article, we interviewed Dr. Kimberly Wicklund, Head of Product Management for the IncuCyte at Sartorius about how live cell analysis is meeting the needs of advanced cell models and how the launch of the new IncuCyte SX1 is providing scientists more options when it comes to using live cell analysis in their workflows. Show Notes We began the podcast by discussing how cell modeling and cell systems have evolved significantly. I asked Dr. Wicklund if she could ex...

In this podcast, we interviewed Dr. Alex Chatel, Product Manager, Viral Applications, Univercells about the biggest challenges facing vaccine manufacturing today, why it is so difficult to manufacture and deliver vaccines to the developing world and how a novel technology with the support of the Gates Foundation is poised to address these challenges. I began the interview by asking Dr. Chatel what he sees as the biggest challenges facing vaccine manufacturing today. He stated that the main chal...

We interviewed Dr. Aline Zimmer, Head of R&D, Advanced Cell Culture Technologies at Merck about the importance of optimizing fed batch cell culture for successful biomanufacturing. Aline discussed how her team has developing new tools and methods for optimizing fed batch culture and the impact this has had on productivity and product quality.

Cell Culture Hero, Dr. Hillary Stires discusses her work researching better treatment options for triple positive breast cancer patients. She explains how the use of cell culture modeling helps drive her research. She also talks about her experience as a cell culture hero and her passion for the scicomm movement on social media platforms.

In this podcast, we interviewed Dr. Rick Morris, Senior Vice President, R&D, Biotech, Pall Life Sciences, about integrating bioprocessing steps to improve efficiency, reduce cost and address current challenges in the industry. Specifically, we looked at how upstream and downstream can be more integrated and how to increase integration in existing facilities. View show notes at cellculturedish.com/integrating-bioprocessing-steps-to-improve-efficiency-and-reduce-cost/

In this podcast, we interviewed Mr. Dave Eansor President of the Protein Sciences Segment at Bio-Techne and Dr. Sean Kevlahan, Senior Director of Cell and Gene Therapy at Bio-Techne about new technologies that can be implemented to expedite cell and gene therapy workflows and facilitate the path from bench to clinic. View show notes at cellculturedish.com/expediting-cell-and-gene-therapy-workflows/

In this podcast, we interviewed Dr. Andreas Castan, Principal Scientist at GE Healthcare Life Sciences about the most efficient ways to optimize fed-batch cell culture production for CHO-based antibodies. This included a discussion of media vs. feed strategies, incorporating critical quality attributes, evaluating the impact of optimizing on downstream processing and more. View show notes at cellculturedish.com/efficient-fed-batch-cell-culture-optimization/

In this podcast, we interviewed Dr. Mats Lundgren, Ph.D. Customer Applications Director, Life Sciences, GE Healthcare, Sweden about developing platform processes for viral vector manufacturing and Mats describes a recently developed platform process for adenovirus production. View show notes at cellculturedish.com/viral-vector-manufacturing-for-gene-therapy-developing-a-platform-process/

This podcast is a recording from the panel discussion that I moderated at this year’s Cell and Gene Therapy Bioprocessing and Commercialization Conference. The discussion covers the latest in gene therapy manufacturing strategies, analytical analysis, cost of goods and key regulatory considerations. View show notes at cellculturedish.com/key-considerations-gene-therapy-manufacturing-commercialization-panel-discussion/

In this podcast, we conducted a panel discussion on key considerations for moving cell therapies from lab to commercial manufacturing, including the benefits of manufacturing in a closed system. We also discussed what were some of the key hurdles and possible solutions associated with transitioning to clinical and commercial cell therapy manufacturing. View show notes at cellculturedish.com/closed-system-cell-therapy-manufacturing-moving-lab-clinical-commercial-production/

In this podcast, we interviewed Dr. Ross Macdonald about the use of mesenchymal stem cells for cell therapy applications and key criteria for successful manufacturing. View show notes at cellculturedish.com/successful-mesenchymal-stem-cell-manufacturing-cell-therapy-applications/